Aim: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for mutation-positive NSCLC.

Materials & Methods: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for -mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.

Results: Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.

Conclusion: Switch use of osimertinib seemed to produce improved efficacy for patients with activating mutations, because of the lack of patient selection via .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186852PMC
http://dx.doi.org/10.2217/lmt-2020-0005DOI Listing

Publication Analysis

Top Keywords

switch osimertinib
8
osimertinib
7
switching second
4
second generation
4
generation egfr-tki
4
egfr-tki osimertinib
4
osimertinib mutation-positive
4
mutation-positive nsclc
4
nsclc aim
4
aim evaluated
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!